Evidence map›Paper›PMID 40694107›Full record

ArticleDer Nervenarzt2025

[Digital health applications in borderline personality disorder].

Gitta Jacob, Eva Fassbinder, Jan Philipp Klein

Erratum issuedAbstract readEnglish Abstract
In one paragraph

Article in Der Nervenarzt, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Erratum issued
    2026
5 · Who and what money

Authors and funding

3 authors.

Gitta JacobGAIA, Hans-Henny-Jahnn-Weg 53, 22085, Hamburg, Deutschland. gitta.jacob@gaia-group.com.
Eva FassbinderPrivatpraxis für Psychische Gesundheit, Lübeck, Deutschland.
Jan Philipp KleinKliniken für Psychiatrie, Psychosomatik und Psychotherapie, Universität zu Lübeck, Lübeck, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital health applications (DiGA) for borderline personality disorder (BPD) are still a relatively new and underresearched topic but hold great potential, especially considering that there is no single approved medication for BPD. So far, one DiGA (priovi) has been permanently approved for BPD by the Federal Institute for Drugs and Medical Devices (BfArM). Concerns related to this topic mainly relate to patient safety and the lack of a therapeutic relationship; however, studies on priovi have actually shown positive findings regarding the therapeutic relationship and its use seems to increase safety rather than compromise it. That said, there is still a significant need for further research in this field. In the practical application each clinician must consider the individual situation of their patient and integrate a DiGA into the treatment plan in a way that seems to best suit the specific patient's needs.

Indexed as

Borderline Personality DisorderMobile ApplicationsTelemedicineDigital HealthEvidence-Based MedicineHumansCrisis interventionSafetySchema therapySkills trainingTherapeutic relationship

Identifiers

PMID40694107
PMCPMC12717144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.